Daniela Caballero Hernandez, a student at the Inés Luaces school, was a little scared, but after the puncture she said: “I’ll tell all my friends that it doesn’t hurt.” Author: Yahili Hernandez Porto
This Saturday, the Committee on Novel Molecules (CMN) of the Federal Commission for Sanitary Risk Protection (Coffepris) gave a positive opinion on the Cuban recombinant protein vaccine Abdala.
The drug, developed by the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba, is indicated for specific active immunization against SARS-CoV-2 infection in children from the age of five, with an efficacy of 92.13% in clinical forms of mild, moderate and severe Covid-19. 88.99% and 92.33%, respectively, according to CMN.
The opinion issued is part of the emergency use authorization process issued by the Sanitary Inspection Commission for Cofepris after evaluating the information provided.
In a statement, Cofepris explained that on April 3, the Abdala vaccine received a positive recommendation from the National Committee for Public Health Science, Technology and Innovation (CNCTI-SP), now the National Council for the Humanities, Sciences and Technology. expansion of indications for emergency use for primary vaccination in the pediatric population from 5 to 17 years.
He explains that since 2021, the Center for State Control of Medicines, Medical Equipment and Devices (Cecmed) of Cuba has authorized the emergency use of said vaccine in that country, confirming that it meets the requirements and parameters required in terms of quality. safety and efficiency.
This health authority reminds the public that the supply of pandemic vaccines is universal and free of charge, and that their use in the country is established in the National SARS-CoV-2 Vaccination Policy for the Prevention of Covid-19. in Mexico.
Source: Juventud Rebelde
